Pfizer COVID-19 vaccine appointments are available to our patients. Sign up for Connect today to schedule your vaccination. Continue your routine care with us by scheduling an in-person appointment or Video Visit.

Milatuzumab: a promising new agent for the treatment of lymphoid malignancies.

TitleMilatuzumab: a promising new agent for the treatment of lymphoid malignancies.
Publication TypeJournal Article
Year of Publication2009
AuthorsMark T, Martin P, Leonard JP, Niesvizky R
JournalExpert Opin Investig Drugs
Volume18
Issue1
Pagination99-104
Date Published2009 Jan
ISSN1744-7658
KeywordsAnimals, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Antigens, Differentiation, B-Lymphocyte, Clinical Trials as Topic, Drug Evaluation, Preclinical, Histocompatibility Antigens Class II, Humans, Immunotherapy, Lymphoma
Abstract

BACKGROUND: Non-Hodgkin's lymphoma and multiple myeloma are often incurable and respond to a limited set of treatment options. The selective expression of CD74, the invariant chain of the MHC class II molecule, in these malignancies provides an attractive target for antibody-based therapy.

OBJECTIVE: This review evaluates the preclinical data for milatuzumab, a humanized antibody targeting CD74, as a treatment for non-Hodgkin's lymphomas and multiple myeloma.

METHODS: A review of the literature was carried out using PubMed. Current Phase I protocols using milatuzumab are summarized.

RESULTS/CONCLUSION: Milatuzumab is cytotoxic to lymphoma and multiple myeloma cell lines and mouse-human xenografts. The efficacy dramatically increases when milatuzumab is attached to a toxin or a radioactive agent. Phase I trials of milatuzumab are now underway in human subjects with lymphoma and multiple myeloma.

DOI10.1517/13543780802636162
Alternate JournalExpert Opin Investig Drugs
PubMed ID19053886